constructs a novel model of SCLC subtypes defined by differential expression of four key transcription regulators: ASCL1, NeuroD1, YAP1, and POU2F3 according to SCLC primary human tumors, patient-derived xenografts, cancer cell lines, and genetically engineered mouse models (2). This evidence concerns the gene NEUROD1 and cancer.